Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benzquinamide is a discontinued antiemetic drug that was primarily used to prevent and treat nausea and vomiting associated with anesthesia and surgery, typically administered intramuscularly or intravenously. It possesses antihistaminic, mild anticholinergic, sedative, and possible antipsychotic properties. The mechanism of action is not fully understood but is presumed to involve antagonism of muscarinic acetylcholine receptor and histamine H1 receptor. Benzquinamide was first synthesized by Pfizer in the 1960s for post-operative care[1][2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzquinamide.